The startup develops diagnostic assays that utilize proteomics and genomics to accurately characterize lung cancer phenotypes. This technology enables oncologists to identify specific biomarkers for tailored therapy selection, improving treatment outcomes for lung cancer patients.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for analyzing patient samples to inform cancer treatment decisions often lack the depth needed to fully understand the proteomic characteristics of the disease. This can lead to less informed treatment decisions and potentially suboptimal outcomes for patients.
Solution
FenoMark Diagnostics provides proteomics solutions that enable medical professionals to gain clinically relevant insights from patient samples using mass spectrometry. Their FenoPrep workflow facilitates high-quality peptide extraction from both fresh/frozen and FFPE tissue or cell samples, enabling the analysis of thousands of proteins. By standardizing methods and tools, FenoMark streamlines the process from sample to analysis and reporting, ensuring quality and consistency. This allows for a deeper understanding of the proteomic data, ultimately empowering medical professionals to make better-informed decisions and advance medical treatments.
Target Audience
The primary target audience includes pathologists, clinical teams, and medical researchers who require robust and reliable protein analysis for clinical research and routine diagnostics.
Features
- FenoPrep: A complete peptide extraction workflow for high-quality peptide extraction.
- Compatible with FFPE and fresh/frozen tissue or cell samples.
- Enables analysis of thousands of proteins from each sample.
- Standardized methods and tools for a streamlined pipeline from sample to analysis.
- Designed to integrate into existing lab workflows with minimal updates or training.
- Developed in collaboration with technology experts and medical professionals.